- About Us
- Contact
- Editorial Staff
- Editorial Boards
- Advertise
- Do Not Sell My Information
- Terms & Conditions
- Privacy Policy
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Christina Mattina
Articles
Dermoscopy Holds Limited Potential to Differentiate BCC From Benign Tumors
September 24, 2022
Article
Despite some differences in the frequency of dermoscopic features between basal cell carcinoma (BCC) and benign skin tumors, dermoscopy alone is not sufficient for a reliable diagnosis, according to a recent study.
ROSEWOOD: Zanubrutinib Combo Provides Superior Efficacy in FL
June 12, 2022
Article
A primary analysis of the phase 2 ROSEWOOD trial finds that a combination of zanubrutinib and obinutuzumab is superior to obinutuzumab alone in relapsed/refractory follicular lymphoma (FL). Results were presented at the 2022 European Hematology Association Congress.
Late-Breaking Abstracts at EHA2022 Describe Therapy Comparisons, Investigational Treatments in Hematology
June 12, 2022
Article
The late-breaking oral session at the 2022 European Hematology Association (EHA) Congress allowed investigators to present recently emerging data from abstracts submitted after the deadline, including outcomes from trials in chronic lymphocytic leukemia, multiple myeloma, and sickle cell disease.
AI Holds Potential to Support Ethical Principles in Hematology—but There’s a Dark Side
June 11, 2022
Article
During a session at the 2022 European Hematology Association Congress, speakers discussed how artificial intelligence (AI) can help advance the principles of ethical medicine—but also how new technologies are being used to undermine the integrity of scientific research.
ALPINE, SEQUOIA Findings: Zanubrutinib Offers Improved HRQOL in CLL/SLL
June 11, 2022
Article
Abstracts presented at the 2022 European Hematology Association Congress demonstrate superior health-related quality of life (HRQOL) outcomes among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) taking zanubrutinib.
Abstracts Demonstrate Long-term, Real-world Advantages of Zanubrutinib in WM
June 10, 2022
Article
In abstracts featured at the 2022 European Hematology Association Congress, investigators detailed long-term results of the ASPEN phase 3 trial and an expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia (WM).
Genetics, Immunophenotyping Help Drive CLL Treatment Selection, but More Knowledge Needed
June 10, 2022
Article
An education session at the 2022 European Hematology Association Congress featured updates on using genetic and immune characteristics to select the optimal treatment pathway in chronic lymphocytic leukemia (CLL).
EHA2022 to Offer Array of Research on Cancer Treatments, Blood Disorders
June 08, 2022
Article
The 2022 European Hematology Association (EHA) Congress will be the group’s first hybrid meeting, in which investigators will convene both virtually and in Vienna, Austria, from June 9-12, 2022, to present cutting-edge findings in the realm of oncology and hematology.
Investigational Biotherapeutic Offers Relief From CDI Recurrence by “Filling in the Cracks” in the Microbiome
May 24, 2022
Article
Abstracts presented at Digestive Disease Week 2022 showed that RBX2660, an investigational microbiota-based drug, was more likely to reduce the recurrence of Clostridioides difficile infection (CDI) compared with placebo.
Reversing Pandemic-Era Trends in Alcoholic Liver Disease Requires Empathetic, Multidisciplinary Care
May 24, 2022
Article
During a State-of-the-Art Lecture at Digestive Disease Week 2022, Jessica L. Mellinger, MD, MSc, explained how the COVID-19 pandemic has driven increases in rates of alcohol use and associated liver disease, as well as what can be done at the clinic, societal, and policy levels to address these trends.